Anthelmintic Mechanisms and Selectivity

Anthelmintics are drugs that kill or expel parasitic worms (helminths). Most act on the worm's neuromuscular system or on structural proteins, exploiting molecular features of nematode, trematode, or cestode physiology that differ from the host's. Their selectivity depends on these differences and on the fact that many of the drugs are poorly absorbed, so they act largely within the gut where intestinal worms live.

Definition

Anthelmintics are agents that act against helminths by disrupting worm-specific neuromuscular signalling, structural proteins, or metabolism, thereby paralysing, starving, or killing the parasite while sparing the host through molecular selectivity or limited host exposure.

Scope

This topic covers the mechanisms of the major anthelmintic classes, the basis of their selective toxicity toward worms, and the molecular changes that produce anthelmintic resistance. It treats anthelmintics as a pharmacological and parasitological reference subject and offers no dosing or treatment recommendations.

Core questions

• What molecular targets do the major anthelmintic classes act on?
• How is selective toxicity toward worms achieved?
• What molecular changes confer anthelmintic resistance?
• Why does limited drug absorption contribute to safety against intestinal worms?

Key concepts

• Benzimidazoles and parasite beta-tubulin binding
• Macrocyclic lactones and glutamate-gated chloride channels
• Cholinergic agonists (tetrahydropyrimidines, imidazothiazoles)
• Praziquantel and calcium-channel disruption in flukes and tapeworms
• Selective toxicity through target divergence and limited absorption
• Anthelmintic resistance mechanisms

Mechanisms

The major anthelmintic classes act on distinct targets. Benzimidazoles bind to beta-tubulin and inhibit microtubule polymerisation, disrupting nutrient uptake and cell division in the worm; selectivity arises because parasite beta-tubulin binds the drug far more avidly than mammalian tubulin. Macrocyclic lactones (the avermectins and milbemycins) open glutamate-gated chloride channels that are present in nematode and arthropod nerve and muscle but absent in mammals, causing flaccid paralysis; their exclusion from the mammalian central nervous system by the blood-brain barrier adds to selectivity. Cholinergic agonists such as the tetrahydropyrimidines and imidazothiazoles stimulate nicotinic acetylcholine receptors at the neuromuscular junction, causing spastic paralysis. Praziquantel disrupts calcium homeostasis in the tegument of flukes and tapeworms, causing contraction and tegumental damage. Resistance arises through target mutation (for example in beta-tubulin or channel subunits), altered drug efflux, or changes in receptor expression.

Clinical relevance

Anthelmintics are the backbone of programmes against soil-transmitted helminthiases, schistosomiasis, and filariases, and understanding their mechanisms underlies the appraisal of efficacy and the monitoring of resistance. This entry explains how anthelmintics act in general terms and is not a guide to selecting, combining, or dosing these drugs for any patient.

Epidemiology

Soil-transmitted helminths and schistosomes infect hundreds of millions of people, mainly in low-income tropical settings, and are controlled largely through periodic mass administration of a small number of anthelmintics. The narrow drug arsenal makes any emergence of human anthelmintic resistance, already widespread in veterinary helminths, a significant concern for control.

History

Modern anthelmintics emerged through twentieth-century discovery: the benzimidazole thiabendazole in the 1960s, levamisole and pyrantel as cholinergic agents, the avermectins from a soil actinomycete in the late 1970s, and praziquantel for flukes and tapeworms. The discovery of avermectin and its derivative ivermectin was later recognised with a share of the 2015 Nobel Prize in Physiology or Medicine. Veterinary experience showed that resistance follows sustained use, foreshadowing concern for human programmes.

Debates

How real is the threat of anthelmintic resistance in human helminths?

Resistance is well documented in livestock parasites, but its extent in human soil-transmitted helminths is harder to measure; experts debate how closely mass drug administration should be monitored and whether reduced efficacy already signals resistance.

Key figures

• Satoshi Omura
• William C. Campbell
• Roger K. Prichard
• Adrian J. Wolstenholme

Seminal works

• geary-2010
• wolstenholme-2004

Frequently asked questions

Why are benzimidazoles relatively safe for the host?

They bind the worm's beta-tubulin with much higher affinity than mammalian tubulin, and several are poorly absorbed from the gut, so they concentrate where intestinal worms live while sparing host cells.

How do ivermectin and related drugs paralyse worms?

They open glutamate-gated chloride channels found in nematode and arthropod nerve and muscle but not in mammals, causing the worm's muscles to relax into a paralysis it cannot recover from.